FDA Approves Voceryq for Rare Respiratory Condition

The new immunotherapy receives accelerated approval to treat adults with recurrent respiratory papillomatosis.

Updated on Oct. 30, 2026 in Cancer

Isometric editorial illustration featuring modular block-like forms representing cellular units, illustrating medical biotechnology approval. — The FDA has granted accelerated approval to Voceryq, an immunotherapy designed to treat adults suffering from recurrent respiratory papillomatosis. AI Illustration. Upload story photo >

Live Poll

Do you trust new immunotherapy treatments to be safe for your own health needs?

The FDA has granted accelerated approval to Voceryq, a plasmid DNA-based immunotherapy, for the treatment of adults suffering from recurrent respiratory papillomatosis. This rare condition is caused by HPV types 6 and 11, which lead to recurring growths in the respiratory tract.

Why it matters

Voceryq works by stimulating the patient's immune system to identify and attack cells infected with specific HPV types, offering a new therapeutic approach for a difficult-to-treat condition. The approval aims to reduce the frequent surgical interventions often required to manage the disease.

In a clinical trial of 32 adults, 7 participants—representing 27% of those with at least three baseline surgeries—required no surgical intervention in the year following treatment. The efficacy was evaluated based on the frequency of surgical procedures.

The players

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs and biological products.

Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals is a biotechnology company focused on developing DNA-based medicines to treat cancer and infectious diseases.

The details

Voceryq is administered via intramuscular injection using the CELLECTRA 5PSP Device, which utilizes electrical pulses to facilitate drug delivery into cell membranes. Common adverse reactions reported during the study include hypertension, dizziness, nausea, headache, fatigue, and injection site reactions.

The FDA granted accelerated approval for the drug on October 30, 2026.
Trial participants were evaluated based on a 12-month qualification period prior to treatment.

Health Landscape

The approval of Voceryq follows the regulatory pathway established by the FDA's Accelerated Approval Program. This process allows for earlier market access for drugs treating serious conditions based on surrogate endpoints, requiring follow-up studies to confirm long-term clinical benefit.

Patients may now have access to an immunotherapy option that potentially reduces the reliance on recurring surgical procedures. Those considering the treatment should discuss common side effects like hypertension and dizziness with their healthcare provider.

The takeaway

Voceryq introduces a targeted immunological approach for managing HPV-driven respiratory papillomatosis. Patients should consult with specialists to determine if this new DNA-based treatment aligns with their specific clinical history.